Actively Recruiting
Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients
Led by Hospital General de Mexico · Updated on 2024-09-19
195
Participants Needed
1
Research Sites
24 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to describe the impact measured through the Odds Ratio (OR) of different variables of clinical and biochemical alterations on the duration of the syndrome alcohol withdrawal patients measured in days of symptoms and stay; it could include any patients with a diagnosis of admission of alcohol withdrawal syndrome (AWS) who have been treated in the department of Internal Medicine for 5 years. The main question it aims to answer is: What is the relationship between the different clinical, biochemical, and hematic factors on the duration of symptoms, morbidity, and mortality in individuals with alcohol syndrome withdrawal? • If the patient has a greater number of risk factors, such as advanced age, a long and chronic history of alcohol consumption, the type of distillate consumed, as well as the deterioration of liver function and presence of leukocytosis and neutrophilia, then it is postulated that the duration of alcohol withdrawal syndrome will be longer. Clinical records will be used to describe the proportion of complications associated with alcohol withdrawal syndrome including pneumonia bronchial aspiration, seizures, need for mechanical ventilation, digestive tract hemorrhage, toxic-alcoholic hepatitis, and pancreatitis.
CONDITIONS
Official Title
Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical records of patients of any gender over 18 years old with Alcohol Withdrawal Syndrome
- Patients admitted for neurological monitoring with criteria for sedative drug use according to the CIWA-Ar scale
- Clinical records must include the CIWA-Ar scale score at diagnosis
You will not qualify if you...
- History of seizures or epilepsy
- Diabetic patients with diabetic ketoacidosis
- Patients who have not received sedative treatment
- Patients with chronic liver failure or liver cirrhosis
- Patients with chronic liver disease showing hepatic encephalopathy
- Patients with toxic-alcoholic hepatitis
- Life expectancy less than 24 hours due to serious complications like head trauma
- Patients requiring intubation and mechanical ventilation upon admission
- Patients with vascular events affecting neurological evaluation
- Patients with psychomotor or neurological deterioration affecting neurological evaluation, including Wernicke's encephalopathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital General de Cuautitlan "General José Vicente Villada"
Mexico City, Mexico, 54800
Actively Recruiting
Research Team
C
Christian O Ramos Peñafiel, PhD
CONTACT
Y
Yossadara Hernández Ángeles, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here